Review Article

Developmental Mechanisms in Articular Cartilage Degradation in Osteoarthritis

Elena V. Tchetina

Institute of Rheumatology, Russian Academy of Medical Sciences, Kashirskoye Shosse 34A, Moscow 115522, Russia

Correspondence should be addressed to Elena V. Tchetina, etchetina@mail.ru

Received 5 August 2010; Accepted 9 December 2010

Academic Editor: Henning Bliddal

Copyright © 2011 Elena V. Tchetina. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Osteoarthritis is the most common arthritic condition, which involves progressive degeneration of articular cartilage. The most recent accomplishments have significantly advanced our understanding of the mechanisms of the disease development and progression. The most intriguing is the growing evidence indicating that extracellular matrix destruction in osteoarthritic articular cartilage resembles that in the hypertrophic zone of fetal growth plate during endochondral ossification. This suggests common regulatory mechanisms of matrix degradation in OA and in the development and can provide new approaches for the treatment of the disease by targeting reparation of chondrocyte phenotype.

1. Introduction

Osteoarthritis (OA) is the most common joint disease, which is associated with a risk of mobility disability. It affects approximately 12% of the aging Western population, while a quarter of people aged over 55 have an episode of persistent knee pain [1]. The pathology of OA involves the whole joint and is associated with focal and progressive hyaline articular cartilage loss, concomitant sclerotic changes in the subchondral bone, and the development of osteophytes. Soft tissue structures in and around the joint including synovium, ligaments, and muscles are also involved [2].

OA affects predominantly articular cartilage, which degrades by gradual loss of its extracellular matrix (ECM) composed mainly of aggrecan and type II collagen. Loss of large proteoglycan aggrecan decreases cartilage compressive stiffness and precedes the damage to collagen fibrillar network, which is responsible for tensile properties of the tissue [3]. Aggrecan degradation is associated with upregulation of aggrecanases a disintegrin and metalloprotease with thrombospondin motifs (ADAMTS-) 4 and 5 as well as matrix metalloproteinases (MMPs) [4]. The excessive cleavage of type II collagen in OA is assumed to be caused by the upregulation of the synthesis and activities of collagenases [5–7], in particular MMP-13 [8–10]. Presently,

it is believed that articular cartilage destruction in OA results from excessive loading, age-related changes, and metabolic imbalance in the tissue [11–13].

OA also exhibits features of a systemic disease as it has been shown to involve vascular pathology [14, 15] as well as T-cell immune response [16, 17] associated with upregulation of cytokines such as interleukin (IL-) β and tumor necrosis factor (TNF) α [3, 18], which aggravate cartilage resorption [19]. As the mechanism of OA development is not completely understood, the disease manifestations, which are associated with cartilage resorption and inflammation, suggest a treatment involving inhibition of proinflammatory cytokines or MMP activity to prevent matrix destruction. However, it does not result in disease modification and produces severe side effects [20, 21].

Articular cartilage degeneration in OA is also associated with changes in chondrocyte phenotype [13, 22, 23]. Specifically, these changes resemble those observed during chondrocyte differentiation in endochondral ossification and are characterized by cell cloning, expression of differentiation-related genes such as parathyroid hormone-related peptide (PTHrP) [24], type X collagen [25–27], annexins and alkaline phosphatase (ALP) [28, 29], osteocalcin [30], matrix calcification [31, 32], as well as apoptotic cell death of terminally differentiated chondrocytes [33, 34]. All these

cellular changes including increased cleavage of type II collagen by MMP-13 are also associated with chondrocyte hypertrophy observed in the growth plate [35]. This suggests that, as articular cartilage shares a common embryological origin with the epiphyseal growth plate [36], destruction of cartilage matrix in OA may involve some of the same cellular and regulatory mechanisms that govern normal chondrocyte terminal differentiation and ECM resorption in skeletal growth and repair [22].

The aim of this paper is to summarize current evidence supporting the involvement of molecular mechanisms observed in the course of chondrocyte progression through the growth plate in cartilage matrix destruction in OA.

2. Zonal Gene Expression in Epiphyseal Growth Plate

A central process in endochondral bone formation is a progressive differentiation of proliferating matrix assembling chondrocytes to growth-arrested hypertrophic cells. This involves remodeling and mineralization of the cartilage matrix and leads eventually to its subsequent replacement by bone.

Primary mammalian growth plate physis is structurally organized and can be divided into zones, namely, the resting, proliferative, and hypertrophic. Resting zone chondrocytes show very limited cell division evidenced by low proliferating cell nuclear antigen (PCNA) expression [37]. They elaborate an extensive extracellular matrix, which is composed predominantly of type II collagen and proteoglycan aggrecan; however, it also contains other collagen types VI, IX, XI, link protein, and small leucine-rich proteoglycans (SLRPs) such as decorin and fibromodulin [37]. Expression of several regulatory growth factors, such as bone morphogenetic proteins (BMPs-) 3, 5, 7, fibroblast growth factor (FGF-) 2, and transforming growth factor (TGF) β 1–3 has been detected in this zone as well [37–43].

In contrast to resting zone, proliferative zone chondrocytes actively divide, which is evidenced by the expression of cyclins [35, 44] and the presence of PCNA positive cells [45]. They produce long columns of flattened cells and express hyaline ECM similar to resting zone chondrocytes. The space for the cells newly formed in the course of cell division is generated by the matrix-degrading activity of collagenases MMP-13, MT1-MMP [46, 47], and other MMPs such as MMP-3 [48]. These cells also express proliferation-specific growth factors, namely, TGF β 1–3, FGF-2 [35, 43, 49, 50], PTHrP, insulin growth factor (IGF-) I and II [35, 51–53], a cell death inhibitor that regulates apoptosis Bcl-2 (B-cell lymphoma-2) [54], and transcription factor Sox9 (SRY-type high-mobility-group box transcription factor 9) [35, 55]. Although PTHrP [56], TGF β 2, and FGF-2 [57, 58] have been reported to stimulate MMP-13 expression in rodents, in the early proliferative zone of the growth plate, their expression does not induce significant matrix loss probably due to the lack of gelatinase (MMP-2 and -9) expression [35, 59].

Cessation of cell division in the growth plate is associated with upregulation of cell cycle inhibitors p18, p19, and p21

[60], growth arrest and DNA damage-inducible (GADD) 45beta gene [61, 62], as well as apoptosis inhibitors Bcl2 and Bag1 (Bcl2-associated athanogene 1), a Bcl2-binding protein capable of enhancing Bcl2 activity [42, 63], and a marker of apoptosis caspase 3 [42]. At this point, chondrocytes partially resorb their extracellular matrix, enlarge, round up, and finally mature into hypertrophic cells, which express type X collagen (COL10A1), a marker of chondrocyte hypertrophy. Alkaline phosphatase shows the most pronounced expression also in hypertrophic chondrocytes [64, 65]. This phenotypic modification in growth plate chondrocytes is associated with dramatic alteration in regulatory gene expression, namely, upregulation of growth factors such as TGF β 1 and -3 [35, 50], BMP-2, -4, -6, and -7 [39, 40, 66–68], connective tissue growth factor (CTGF) [69], vascular endothelial growth factor (VEGF) [59, 70], and Indian hedgehog (Ihh) [35, 71, 72]. Inflammation-related cytokine IL-1 expression also has been observed only in the hypertrophic chondrocytes [73].

These regulatory growth factors are expressed in association with runt-related transcription factor (RUNX)2, which is essential both for osteoblast differentiation [74] and chondrocyte maturation during endochondral ossification [75–78], and is capable of inducing MMP-13 expression [79, 80].

Expression of these growth and transcription factors is also associated with upregulation of matrix proteins, such as collagen type II (COL2A1) concomitantly with their degrading enzymes MMP-13 and gelatinases MMP-2 and -9 [35, 67]. At this time, overt type II collagen degradation occurs [46] indicating that genes for both matrix synthesis and degradation are coregulated. However aggrecan remains retained in the tissue at that time [3].

In the lower hypertrophic zone, mineralization (or calcification) of residual matrix remaining after its resorption is initiated focally [3]. This involves deposition of hydroxyapatite mineral [81]. Mineralization process in the lower hypertrophic zone of the growth plate is associated with expression of osteocalcin, which is a marker of mature osteoblasts and is involved in chondrocyte mineralization and Ca²⁺ homeostasis [28]. Upregulation of ankylosis protein (Ank), which is responsible for transport of intracellular inorganic pyrophosphate to the extracellular milieu, has been also observed in this zone [82]. Mineralization is likely regulated by annexins II, V, and VI, which are highly expressed in the hypertrophic and terminally differentiated mineralizing growth plate chondrocytes and form calcium channels enabling formation of first mineral phase [83, 84]. For example, annexin V has been shown to be capable of upregulating annexins II, VI, osteocalcin, Runx2, and ALP as well as stimulating apoptotic activity in the lowest part of the growth plate [83, 85]. In contrast, TGF β 2, which is also expressed by lower hypertrophic chondrocytes [35], is most probably involved in osteoblast formation [86].

Therefore, chondrocyte maturation in the growth plate is associated with expression of stage-specific set of regulatory growth and transcription factors producing changes in cellular phenotype and synthesis of stage-specific extracellular matrix, which eventually degrades in the hypertrophic

zone. All these cellular activities require careful and specific coordination.

3. Regulation of Growth Plate Chondrocyte Differentiation

Chondrocyte differentiation is initiated in the center of the cartilaginous bone rudiment and is thought to be induced by hypoxia and/or nutrient deficiency [87]. The pace of chondrocyte differentiation is regulated by various agents including paracrine and autocrine growth factors and hormones [3, 88]. They are responsible for specific regulatory molecule expression by chondrocytes in the course of their progression through the growth plate.

Growth factors secreted by fetal chondrocytes are in charge of mutually exclusive processes of chondrocyte proliferation and terminal differentiation. Thus, proliferation-related growth factors such as basic fibroblast growth factor and parathyroid hormone-related peptide stimulate resting chondrocytes to proliferate and suppress terminal differentiation of hypertrophic chondrocytes [89–96]. In addition, PTHrP, in combination with Indian hedgehog, regulates chondrocyte differentiation through the establishment of a negative feedback mechanism, whereby Ihh and PTHrP can together suppress hypertrophy [97–100]. Alternatively, interactions of Ihh with syndecan 3, which serves as a growth factor coreceptor, are important for restricting mitotic activity to the proliferative zone of mammalian growth plate [101].

Transforming growth factor betas are multifunctional molecules regulating cellular proliferation, differentiation, and extracellular matrix function [75, 102]. TGF β transported from apoptotic chondrocytes to the region of cell division would be expected to stimulate matrix production, delay hypertrophic differentiation, and thus maintain growth plate width [103, 104]. TGF β 1 [105–107] and TGF β 2 [108] each are able to suppress chondrocyte hypertrophy by coordinate inhibition of collagenase expression. This is partially associated with upregulation of PTHrP gene expression that exerts both PTHrP-dependent and PTHrP-independent effects on endochondral bone formation [105, 109, 110]. TGF β 2 in synergy with FGF-2 has been also shown to suppress chondrocyte maturation and hypertrophy [111, 112].

BMP signaling is also essential for chondrocyte progression through the growth plate [66]. Zone specific expression of various BMPs suggests their involvement in chondrocyte phenotypic changes in the course of both proliferation and hypertrophy. Thus, BMP-2 and -6 have been shown to promote chondrocyte hypertrophy by upregulation of Ihh and type X collagen expression and downregulation of FGF signaling involving Runx2 [113–118]. At the same time, BMP-2 and -9 augmented mitogenic effect of IGF-1, while BMP-5 increased cell proliferation and cartilage matrix synthesis [119, 120].

IGF-1, a structural and functional analog of insulin, promotes chondrocyte proliferation and differentiation while it inhibits apoptosis [89, 93]. It is also an important

regulator of PTHrP-Ihh feedback loop. The lack of IGF results in downregulation of Ihh expression and upregulation of PTHrP [51]. IGF-1 favors chondrocyte hypertrophic development as it induced type X collagen and alkaline phosphatase in avian sternal chondrocytes [108, 112]. In addition, insulin and IGF-1 [121] both are strong stimulators of aggrecan and type II collagen synthesis [122].

Furthermore, chondrocyte differentiation in the growth plate is regulated by various transcription factors [123]. Transcription factors Sox9 and -4 have been shown to determine the rate of chondrocyte differentiation into hypertrophy and the expression of chondrocyte-specific matrix molecules including Col2A1, Col9A2, Col11A1, and aggrecan [124–130]. They are also required to prevent conversion of proliferating chondrocytes into hypertrophic chondrocytes [55]. Transcription factors Runx1-3 are the most important as they play a crucial role both in chondrocyte maturation and had been shown to induce MMP-13 expression [77, 80, 125, 131]. Recently, the involvement of several other transcription factors such as Shox/Shox2, Dlx5, and MEF2C has been shown to control skeletal growth that suggests their potential contribution in ectopic chondrocyte hypertrophy development [132, 133]. Wnt/beta-catenin signaling can also mediate chondrocyte hypertrophy as it is capable of upregulating type X collagen, Runx2, and alkaline phosphatase expression while inhibiting Sox9 and type II collagen expression [92].

Prostaglandin E2 (PGE2), a potent lipid molecule that regulates a broad range of physiologic reactions, can inhibit growth plate chondrocyte differentiation by downregulation of differentiation-related genes COL10A1, VEGF, MMP-13, and alkaline phosphatase expression as well as their enzyme activity [134, 135]. At the same time, low concentrations of this prostaglandin are capable of increasing proliferation of growth plate chondrocytes [136, 137]. In contrast, chemokine stromal cell-derived factor 1, annexin V, and Ank have been shown to stimulate hypertrophy, mineralization, and apoptosis, when they are overexpressed in nonmineralizing growth plate chondrocytes [82, 85, 138, 139].

Extracellular matrix proteins produced by chondrocytes have also exhibited a capacity to regulate growth plate chondrocyte hypertrophy. Thus, type II collagen, aggrecan, and matrilin-3 are likely to inhibit hypertrophy as these matrix component deficiency produced premature maturation in mutant chondrocytes [140–142]. Furthermore a functional link between chondrocyte hypertrophy and extracellular matrix degradation is also supported by the fact that downregulation of chondrocyte hypertrophy evidenced by suppression of type X collagen, Runx2 and MMP-13 expression is associated with inhibition of collagen cleavage activity in cultured hypertrophic growth plate chondrocytes treated with MMP-13 inhibitor [8, 143, 144]. This indicates a functional link between chondrocyte hypertrophy and extracellular matrix degradation.

It is necessary to note that variable effects of regulatory molecules are carefully coordinated to provide accuracy in the process of endochondral ossification. Thus, it has been demonstrated that growth plate chondrocyte progression

to hypertrophy is a subject to negative control that can be arrested at various checkpoints [112]. Accordingly, an early proliferative phenotype in avian fetal chondrocytes has been reassumed by treatment with TGF β 2, FGF-2, and insulin in combination, while differential Ihh expression was responsible for acquisition of the late proliferative phenotype in hypertrophic cells [112]. In another study, the release of terminally differentiated hypertrophic chondrocytes from their environment also resulted in downregulation of type X collagen synthesis, activation of proliferation, and reinitiation of aggrecan synthesis [145].

Therefore, chondrocyte differentiation is carefully regulated in the course of endochondral ossification. Eventually, epiphyseal chondrocytes give rise to articular cartilage, whose structural components and regulatory networks at least partially resemble that in the growth plate.

4. Zonal Gene Expression in Healthy Articular Cartilage

Healthy articular cartilage is characterized by a very low expression of collagens type II, VI, IX, and XI [146] and relatively high turnover rate for aggrecan [147]. It is also characterized by expression of matrix turnover genes such as MMP-3 [148], occasionally detected MMP-1, -8, -13 [149], and growth factors TGF β 1 [150] and PTHrP [24, 151]. Antiangiogenic factor chondromodulin-1 [152, 153], p16INK4 α , and Gadd45 α/β genes, the latter is associated with environmental and intrinsic stress [154, 155], are expressed in all the cartilage zones. At the same, time no expression of type I and X collagens [156, 157], a complete lack of expression of TGF β 2, IGF-1, Ihh [158, 159], annexin VIII [160], and osteocalcin [30] was observed in healthy cartilage.

Articular cartilage can be divided into superficial, mid-, and deep zones; the latter is followed by the calcified cartilage providing junction of the cartilage to the subchondral bone [157]. These zones differ in expression of specific matrix molecules, their modifying enzymes, and regulatory growth factors, which are responsible for articular cartilage integrity and function. Although normal articular chondrocytes are less metabolically active than the growth plate chondrocytes, some similarity in gene expression pattern in the individual cartilage zones has been noted.

Superficial zone of healthy articular cartilage contains flattened chondrocytes surrounded by specialized extracellular matrix rich in thin collagen fibrils [161] and small leucine-rich proteoglycans-decorin and biglycan [162]. It also contains the lowest amount of predominant cartilage proteoglycan aggrecan compared to other zones of articular cartilage. This zone is rich in regulatory molecules such as TGF β 1 and -3 and BMP 1–6 [37, 40]. Proliferative potential of these cells is indicated by the expression of cyclin D2; however, it may be suppressed by cell division inhibitors such as growth arrest specific protein (Gas)-1 and Gadd45 α , which are also expressed in this cartilage zone [37]. This is supported by the lack of superficial chondrocyte proliferative activity determined by PCNA staining [163].

MMP-3 expression was observed in this cartilage zone more often than MMP-1, -8, and -13, however these proteinases do not produce any matrix degradation and are likely involved in matrix turnover [149, 164]. Expression of antiapoptotic Bcl2 and Bag1 genes was detected predominantly in this zone in old mice, while it was observed throughout the articular cartilage in the young animals [63].

Mid-zone chondrocytes are round in shape, surrounded by ECM composed of thick collagen fibrils and rich in aggrecan. Chondrocytes in this zone do not show any proliferative activity determined by PCNA staining similar to superficial zone cells [163]. However, these cells are likely to possess a potential for proliferation, as FGF-2, capable of inducing proliferation in normal articular chondrocytes in culture [165], has been detected in the mid-zone of mouse articular cartilage [49]. BMP1–7 expression was also observed in the mid-zone of normal articular cartilage [40].

Deep zone chondrocytes are grouped in clusters and resemble hypertrophic chondrocytes of the growth plate [3]. In this zone, cartilage matrix has the highest content of aggrecan [166], the lowest amounts of small leucine-rich proteoglycans [162], and the largest diameter of collagen fibrils. Similar to hypertrophic zone of the growth plate, BMP1–7 [40], Ihh expression [167], and the highest amount of annexin VI-positive cells were observed in the deep zone of human articular cartilage [163]. The lowest part of the deep zone, which is partly calcified, expressed a marker of chondrocyte hypertrophy type X collagen and is rich in alkaline phosphatase. MMP-13 expression [149] and negligible activity of chondrocyte apoptosis was also sometimes observed here [168, 169].

However, in spite of low activity of cellular and matrix turnover, healthy articular cartilage possesses a strong metabolic potential, whose activation is observed during development of pathological condition such as OA.

5. Early Development of Osteoarthritis

Early OA changes in articular cartilage are associated with significant metabolic activation of articular chondrocytes. This involves sequential and zonal upregulation of chondrocyte differentiation-related genes as well as an increase in the activity of the same MMPs, which are responsible for matrix degradation in the hypertrophic zone of the growth plate. Spatially, these genes are upregulated in the mid- and superficial zones of articular cartilage, where lately the first signs of cartilage destruction occur.

Mild OA changes (Mankin 1–4) are characterized by the loss of proteoglycans in the surface area [163, 170, 171]. Although these changes were not accompanied by significant structural disturbances in the tissue, they were associated with increased type II collagen and aggrecan synthesis, upregulation of chondrocyte proliferation evidenced by increased PCNA and Ki67 staining and MMP-13 expression [172–175]. This was followed by the cellular changes similar to those observed in hypertrophic zone of the growth plate as indicated by type X collagen production, collagenase

and alkaline phosphatase staining, and increased type II collagen cleavage activity in the mid-zone [172, 176]. Later, chondrocyte activation extends to the superficial zone, where it is accompanied by chondrocyte apoptosis evidenced by the presence of the cells carrying DNA nicks [172]. IL-1 β expression is also upregulated both in the superficial and deep cartilage zones in early OA [177]. Similar to biphasic MMP-13 expression in the growth plate, upregulation of this collagenase in the articular cartilage was initially preceded and later accompanied by type X collagen and alkaline phosphatase expression [172, 176].

An early OA articular cartilage degeneration is observed focally. Spatial distribution of chondrocyte differentiation-related gene expression in the areas adjacent to and remote from the early lesion also resembles that in the growth plate and is associated with increased collagenase cleavage of type II collagen. Thus, collagenases MMP-1, MMP-14 (MT1-MMP), and aggrecanase ADAMTS-5 (but not ADAMTS-4), cytokines IL-1 α/β and TNF- α , chondrocyte terminal differentiation-related genes COL10A1, MMP-13, MMP-9, *Ihh*, and caspase 3 were often upregulated in the vicinity of the lesion. Growth factors associated with growth plate chondrocyte proliferation, namely, FGF-2, PTHrP, and TGF β 1/2, as well as the matrix molecules COL2A1 and aggrecan, were expressed adjacent to and remote from the lesion [22]. In addition, a distinct spatial reorganization in human superficial chondrocytes in remote area from early OA lesions has been recently reported [178].

However, of all genes, only caspase 3 and ADAMTS-5 expression was exclusively seen in association with early lesions. Elevation of collagenase activity was associated with a frequent elevation of expression of COL10A1, caspase 3, IL-1 α/β , MMP-1, and ADAMTS-5 and a decreased expression of Sox-9, TGF- β 1, TGF- β 2, TNF- α , and aggrecan [22].

Moderate OA changes in the articular cartilage (Mankin 6–9), which are characterized by the lack of fibrillations, some loss of superficial zone, and some clustering of cells [163, 171], are associated with the increase of PCNA staining in the superficial zone and annexin VI and VIII antigen upregulation in the mid- and deep zones [160, 163, 179].

Therefore, articular chondrocyte activation in early OA, which is the most pronounced in the superficial and mid-zones, resembles that observed during chondrocyte maturation in the growth plate.

6. Gene Expression in Late Osteoarthritic Cartilage

Severe OA (Mankin ≥ 10) is characterized by extensive fissuring and fibrillation, clustering of chondrocytes, and loss of cartilage [163]. Cartilage zonal organization is disturbed. The superficial zone degradation produces rough fibrillated surface, fissures, and cracks extending to the calcified zone. This is accompanied by severe proteoglycan loss followed by degradation of type II collagen [164, 180]. Collagen degradation occurs around chondrocytes. At this time, upregulation of MMPs-13, -2, -11, ADAMTS as well as expression of collagens type I, II, III, VI, and X were

observed near the articular surface [148, 181–183] and was accompanied by strong expression of IL-1 β and TNF α [149]. At the same time, collagen replenishment is limited as Col2A N-propeptide, a marker of collagen synthesis, was detected only in the deep zone close to subchondral bone [184]. As it was stated above, all these gene activities have been also observed in the hypertrophic zone of the fetal growth plate.

Chondrocyte terminal differentiation-related gene expression is also observed in cell clusters located around fissures [185, 186]. In these clusters, both collagen type II and X synthesis [187] as well as TGF β 3 and its receptor regulator Smad-2P expression were observed [188].

PCNA and syndecan-3, the markers of early fetal chondrocyte differentiation, as well as annexin VI and alkaline phosphatase, which are involved in terminal stage of differentiation, all are upregulated near articular surface in human OA articular cartilage [30, 163]. At the same time, annexin VIII and osteocalcin, which were never detected in normal articular cartilage, were observed in the mid- and deep zones in late OA cartilage [30, 160]. An increase in BMP-2 expression [188] was associated with upregulation of tumor suppressor p53 expression [189] and cyclin-dependent kinase inhibitor p16INK4a upregulation in all the cartilage zones [155] indicating inhibition of proliferative potential in late OA chondrocytes. However, repression of antiproliferative factor Tob1 has been also reported in the late stage of knee OA cartilage [183].

The most severely damaged rodent knee OA articular cartilage has shown significantly reduced expression of proliferation-related growth factors and their signaling molecules such as PTHrP, TGF β 3 and Smad-2P, TGF β 1 and its receptor II [188, 191]. However, in human hip OA, both downregulation and upregulation of TGF β 1–3 isoform expression compared to healthy cartilage have been reported [43, 192], while one study failed to detect any upregulation of chondrocyte differentiation and hypertrophy markers associated with late OA [193].

Antiangiogenic factor chondromodulin-1 downregulation concomitant to VEGF upregulation indicating increased vascular invasion into cartilage in advanced OA has been also observed [194, 195]. This was accompanied by upregulation of chondrocyte apoptosis, a marker of the final step of chondrocyte differentiation, which was more pronounced in OA cartilage compared to normal specimens [189].

Overall degrading activity prevailed over synthesis as serum levels of Col2A N-propeptide were lower than that of collagen degradation products in late OA patients compared to controls indicating the uncoupling of collagen synthesis and degradation in OA [190]. Moreover, serum increase in both Col2A N-propeptide and collagen degradation fragments was often indicative on the most aggressive disease progression [196].

Thus, the similarity in the gene expression profiles associated with matrix destruction in OA articular cartilage and in the hypertrophic zone of the growth plate observed in the majority of studies suggests an acquisition of hypertrophic phenotype traits by OA articular chondrocytes.

7. Inhibition of Articular Chondrocyte Hypertrophy Suppresses OA Cartilage Degeneration

The similarity of ECM degradation in OA to that in the hypertrophic zone of primary growth plate involves upregulation of type II collagen cleavage by collagenase and expression of regulatory differentiation-related growth factors and matrix proteins, which are associated with chondrocyte hypertrophy [6, 22, 25, 28]. Therefore, the above observation that hypertrophic changes in the growth plate chondrocytes are reversible [112] suggests a possibility for OA articular chondrocytes to regain healthier phenotype when they are treated by the agents inhibiting fetal hypertrophy.

In fact, the same growth factors, namely, TGF β 2, FGF-2, and insulin, which were previously used individually or in combination to suppress hypertrophy in growth plate chondrocytes [112], have been shown to be capable of arresting type II collagen cleavage, chondrocyte differentiation-related gene, and proinflammatory cytokine expression in human OA articular cartilage explants [197]. Another combination of TGF β 1 and IGF1 inhibited collagen degradation, a marker of extracellular matrix destruction, which was induced by oncostatin M and TNF α in bovine articular cartilage [198]. It has been also shown that TGF β inhibition of chondrocyte differentiation is likely mediated by Smad2/3 pathway through modulation of Runx2 function [75]. In another study, a major proliferation-related growth factor PTHrP downregulated terminal differentiation-related genes in cultured mineralizing articular chondrocytes from the deep zone as well as in chondrogenic articular cartilage constructs [199, 200]. It is worth to note here that growth factors, which were capable of inhibiting collagen degradation in OA articular cartilage, are predominantly expressed in the proliferative zone of the growth plate and are required for chondrocyte proliferation in the development.

Similar effect on suppression of collagen cleavage in association with inhibition of chondrocyte hypertrophy-related genes and proinflammatory cytokines IL-1 β and TNF α has been observed on treatment of OA explants with low concentrations of PGE2 [201]. Although PGE2 is expressed in all the growth plate zones, it is primarily required for fetal chondrocyte proliferation [137] and is capable also of inhibiting their terminal differentiation [134, 135] and expression of proinflammatory mediators [202]. At the same time, PGE2 at higher concentrations has been shown to exert stimulating effects on cartilage degradation [203].

Alternatively, downregulation of the genes, which are expressed in the hypertrophic zone of the growth plate and associated with chondrocyte terminal differentiation such as Hedgehog signaling, TGF β 1/BMP signaling, transforming growth factor-beta-activated kinase (TAK) 1, cyclin-dependent kinase inhibitor p16INK4a, ADAMTS5, RUNX2, and caspases, resulted in abrogation of matrix degeneration, less type X collagen production, and MMP-13 expression [155, 204–210]. Therefore, upregulation of the genes associated with growth plate chondrocyte proliferation or downregulation of hypertrophy-related genes favors acquisition of healthier phenotype in OA articular chondrocytes.

However, while direct inhibition of cartilage degradation by the agents capable of regulating chondrocyte differentiation is an attractive means to counteract articular cartilage degeneration in OA, it has several limitations. Thus, following the inhibition of cartilage degradation by individual growth factors (GFs) repair of articular cartilage in OA in vivo may require a combination of GF [18, 211, 212]. For example, being the most efficient in suppressing OA articular cartilage destruction [197], TGF β 2 alone may not be capable of restoring the anabolic functions of healthy articular cartilage since it has been reported to downregulate type II collagen and aggrecan synthesis [108, 213]. In contrast, in responsive individuals, insulin may facilitate tissue repair as it is a principal anabolic agent in the articular cartilage [214]. FGF-2 can also promote cartilage repair [212] by itself or inducing local TGF β or its own expression [215]. In addition, combinations of these and other growth factors have been shown to produce synergistic effect in maintaining synthesis of matrix molecules in articular and growth plate chondrocytes [108, 216, 217].

Another concern on GF application is related to their possible catabolic effects. Although no evidence has been obtained that TGF β 2 can act catabolically in human OA articular cartilage [197], destructive potential of this growth factor at high concentration was observed in normal articular cartilage in vivo after its intraarticular injections, which produced joint swelling, fibroblastic proliferation of synovial membrane, and profound loss of articular cartilage proteoglycan in rabbit joints [213]. Therefore, the delivery of exact therapeutic amount of the growth factor to the site of articular cartilage destruction may be important. This has been demonstrated in a recent study, where deleterious effect of TGF β 1 capable of inducing synovial fibrosis has been counteracted by combined overexpression of TGF β 1 and its inhibitor Smad7 [188]. This resulted both in prevention of proteoglycan (PG) loss and in increase in PG content in mouse OA cartilage.

8. Modeling of OA-Related Changes in Healthy Articular Cartilage Is Associated with Chondrocyte Hypertrophy Development

In healthy adult articular cartilage, chondrocyte differentiation does not occur in the noncalcified cartilage [218]. However, when maturational arrest is abolished, chondrocyte differentiation-related genes, which are barely expressed in healthy articular cartilage, become upregulated followed by hypertrophic changes in the cells and extracellular matrix. If this notion is true, stimulation of degradation in healthy articular cartilage should be accompanied by chondrocyte hypertrophy development. The relieve of transcriptional repression can be attained by cartilage treatment with azacytidine C (Aza-C), which replaces cytidine bases in genomic DNA during replication and disturbs methylation pattern of cytidines (CpG islands) in target gene promoters. This was associated with upregulation of PTHrP, governing chondrocyte proliferation in the growth plate, as well as chondrocyte hypertrophy-related collagen type X, Ihh, and

alkaline phosphatase gene expression, and the increase in chondrocyte cell size in healthy articular cartilage [219–221].

On the other hand, alterations associated with chondrocyte hypertrophy in the growth plate are always accompanied by overt extracellular matrix resorption producing its degradation fragments [3]. Therefore, it is not surprising that collagen and/or fibronectin degradation peptides, which can be also released on mechanical destruction of articular cartilage caused by trauma or joint overload in case of anterior cruciate ligament transection, have been shown to be capable of inducing articular cartilage degradation by upregulation of collagenase and MMPs activity [222–224]. Besides, these peptides upregulated chondrocyte proliferation, production of type X collagen and apoptotic cells on the surface of articular cartilage explants [172, 224]. Collagen fragments may also account for OA-like changes induced in healthy cartilage by overexpression of MMP-13, which were associated with chondrocyte hypertrophy in mouse articular cartilage [47]. In addition, other matrix disturbances such as lack of matrilin-3 by a corresponding gene knockout produced premature chondrocyte maturation to hypertrophy and formed predisposition to develop severe OA in mice [141].

Functional disturbances in the regulatory genes involved in chondrocyte differentiation can also produce OA-related changes in healthy articular cartilage resembling chondrocyte maturation in the growth plate. Thus, deficiency in TGF β signaling, which is essential for articular cartilage maintenance and had been induced either by overexpression of functionless TGF β type II receptor [225] or by deletion of Smad3 signaling [104, 226], caused accelerated chondrocyte differentiation associated with type X collagen expression and OA-like changes in articular cartilage. It has been also shown that the absence of signaling through Fgfr (fibroblast growth factor receptor) 3 in the joints of Fgfr3(–/–) mice produced premature cartilage degeneration and early arthritis [227]. In contrast, TGF α signaling suggests catabolic potential of this growth factor as it has been shown to stimulate articular chondrocyte proliferation, formation of cell clusters followed by expression of matrix-degrading enzymes MMP-13, cathepsin C and downregulation of Sox9, as well as collagen and aggrecan expression in rat articular osteochondral explants [228].

Being an important factor of OA articular cartilage pathology proinflammatory cytokines such as TNF α and IL-1 β have been shown to mediate articular cartilage degradation by upregulation of matrix-degrading MMPs [229]. It has been observed recently that increased expression of proinflammatory agents such as TNF α , chemokines IL-8, growth-related oncogene α (GRO α), or the multiligand receptor for advanced glycation end products (RAGE) induced also chondrocyte hypertrophy evidenced by collagen type X expression [230, 231]. This suggests a link between inflammation and altered differentiation in articular chondrocytes [231]. Interestingly, the impairment TGF β signaling by IL-1 β was mediated by downregulation of TGF β RII [232]. The loss of function of this receptor has previously been linked to chondrocyte hypertrophy induction and OA development in animal studies [225].

Therefore, OA-like alterations in healthy articular cartilage induced by the mediators, which are upregulated in the hypertrophic zone during endochondral ossification, are accompanied by ECM degradation and associated with articular chondrocyte hypertrophy.

9. Conclusions

The data presented here shows a significant progress in our understanding of molecular mechanisms of articular cartilage degradation in OA. They involve at least in part similar machinery of extracellular matrix resorption in the hypertrophic zone of the growth plate and in OA articular cartilage in the course of its degeneration. The observation that profound cellular phenotypic changes in articular chondrocytes occur prior the overt cartilage matrix degradation monitored histologically suggests that articular chondrocyte phenotype modifications can be recognized very early in the disease at gene expression level favoring timely disease recognition, which could help its prevention. This implies also innovative opportunities in suppression of cartilage matrix degradation targeting inhibition of chondrocyte hypertrophy and suggests new targets for therapeutic intervention. For this purpose, further studies are required in search of new agents generating programmable articular chondrocyte phenotype modification.

Abbreviations

OA:	Osteoarthritis
ECM:	Extracellular matrix
MMP:	Metalloproteinases
IL:	Interleukin
ADAMTS:	A disintegrin and metalloprotease with thrombospondin motifs
PTHrP:	Parathyroid hormone-related peptide
TNF:	Tumor necrosis factor
ALP:	Alkaline phosphatase
PCNA:	Proliferating cell nuclear antigen
SLRPs:	Small leucine-rich proteoglycans
BMP:	Bone morphogenetic protein
FGF:	Fibroblast growth factor
TGF:	Transforming growth factor
TGFR:	Transforming growth factor receptor
IGF:	Insulin growth factor
Bcl-2:	B-cell lymphoma 2
Sox9:	SRY-type high-mobility-group box transcription factor-9
GADD45beta:	Growth arrest and DNA damage-inducible 45beta
Bag1:	Bcl2-associated athanogene 1, a Bcl2-binding protein capable of enhancing Bcl2 activity
COL10A1:	Type X collagen
BMP:	Bone morphogenetic proteins
CTGF:	Connective tissue growth factor
VEGF:	Vascular endothelial growth factor
Ihh:	Indian hedgehog
RUNX2:	Runt-related transcription factor

COL2A1: Collagen type II
 Ank: Ankylosis protein
 PGE2: Prostaglandin E2
 Gas1: Growth arrest specific protein1
 Aza-C: Azacytidine C
 Fgfr3: Fibroblast growth factor receptor 3
 RAGE: Multiligand receptor for advanced glycation end products
 GRO: Growth-related oncogene
 PG: Proteoglycan
 TAK: Transforming growth factor-beta-activated kinase
 GF: Growth factor.

Acknowledgment

The author is supported by the Russian Foundation for Basic Research (Project no. 09-04-01158a).

References

- [1] D. J. Hunter and D. T. Felson, "Osteoarthritis," *British Medical Journal*, vol. 332, no. 7542, pp. 639–642, 2006.
- [2] S. B. Abramson and M. Attur, "Developments in the scientific understanding of osteoarthritis," *Arthritis Research & Therapy*, vol. 11, no. 3, article 227, 2009.
- [3] A. R. Poole, "Cartilage in health and disease," in *Arthritis and Allied Conditions: A Textbook of Rheumatology*, W. Koopman, Ed., pp. 223–269, Lippincott, Williams & Wilkins, Philadelphia, Pa, USA, 15th edition, 2005.
- [4] H. Nagase and M. Kashiwagi, "Aggrecanases and cartilage matrix degradation," *Arthritis Research & Therapy*, vol. 5, no. 2, pp. 94–103, 2003.
- [5] A. R. Poole, F. Nelson, L. Dahlberg et al., "Proteolysis of the collagen fibril in osteoarthritis," *Biochemical Society Symposium*, no. 70, pp. 115–123, 2003.
- [6] A. R. Poole, F. Guilak, and S. B. Abramson, "Etiopathogenesis of osteoarthritis," in *Osteoarthritis: Diagnosis and Medical/Surgical Management*, R. W. Moskowitz, R. D. Altman, M. C. Hochberg, J. A. Buckwalter, and V. M. Goldberg, Eds., pp. 27–49, Williams & Wilkins, Lippincott, Pa, USA, 4th edition, 2007.
- [7] A. R. Poole, M. Kobayashi, T. Yasuda et al., "Type II collagen degradation and its regulation in articular cartilage in osteoarthritis," *Annals of the Rheumatic Diseases*, vol. 61, no. 2, pp. ii78–ii81, 2002.
- [8] C. W. Wu, E. V. Tchetina, F. Mwale et al., "Proteolysis involving matrix metalloproteinase 13 (collagenase-3) is required for chondrocyte differentiation that is associated with matrix mineralization," *Journal of Bone and Mineral Research*, vol. 17, no. 4, pp. 639–651, 2002.
- [9] R. C. Billingham, L. Dahlberg, M. Ionescu et al., "Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage," *Journal of Clinical Investigation*, vol. 99, no. 7, pp. 1534–1545, 1997.
- [10] L. Dahlberg, R. C. Billingham, G. Webb et al., "Selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1)," *Arthritis and Rheumatism*, vol. 43, no. 3, pp. 673–682, 2000.
- [11] T. Aigner, J. Haag, J. Martin, and J. Buckwalter, "Osteoarthritis: aging of matrix and cells—going for a remedy," *Current Drug Targets*, vol. 8, no. 2, pp. 325–331, 2007.
- [12] T. Aigner and N. Gerwin, "Growth plate cartilage as developmental model in osteoarthritis research potentials and limitations," *Current Drug Targets*, vol. 8, no. 2, pp. 377–385, 2007.
- [13] P. M. van der Kraan, E. N. Blaney Davidson, and W. B. van den Berg, "A role for age-related changes in TGF-beta signaling in aberrant chondrocyte differentiation and osteoarthritis," *Arthritis Research & Therapy*, vol. 12, no. 1, pp. 201–214, 2010.
- [14] D. M. Findlay, "Vascular pathology and osteoarthritis," *Rheumatology*, vol. 46, no. 12, pp. 1763–1768, 2007.
- [15] P. Ghosh and P. A. Cheras, "Vascular mechanisms in osteoarthritis," *Best Practice and Research: Clinical Rheumatology*, vol. 15, no. 5, pp. 693–709, 2001.
- [16] H. de Jong, S. E. Berlo, P. Hombrink et al., "Cartilage proteoglycan aggrecan epitopes induce proinflammatory autoreactive T-cell responses in rheumatoid arthritis and osteoarthritis," *Annals of the Rheumatic Diseases*, vol. 69, no. 1, pp. 255–262, 2010.
- [17] L. I. Sakkas and C. D. Platsoucas, "The role of T cells in the pathogenesis of osteoarthritis," *Arthritis and Rheumatism*, vol. 56, no. 2, pp. 409–424, 2007.
- [18] C. J. Malemud, "Anticytokine therapy for osteoarthritis: evidence to date," *Drugs and Aging*, vol. 27, no. 2, pp. 95–115, 2010.
- [19] M. Kobayashi, G. R. Squires, A. Mousa et al., "Role of interleukin-1 and tumor necrosis factor α in matrix degradation of human osteoarthritic cartilage," *Arthritis and Rheumatism*, vol. 52, no. 1, pp. 128–135, 2005.
- [20] C. B. Little and A. J. Fosang, "Is cartilage matrix breakdown an appropriate therapeutic target in osteoarthritis—insights from studies of aggrecan and collagen proteolysis?" *Current Drug Targets*, vol. 11, no. 5, pp. 561–575, 2010.
- [21] R. F. Loeser, "Molecular mechanisms of cartilage destruction in osteoarthritis," *Journal of Musculoskeletal Neuronal Interactions*, vol. 8, no. 4, pp. 303–306, 2008.
- [22] E. V. Tchetina, G. Squires, and A. R. Poole, "Increased type II collagen degradation and very early focal cartilage degeneration is associated with upregulation of chondrocyte differentiation related genes in early human articular cartilage lesions," *Journal of Rheumatology*, vol. 32, no. 5, pp. 876–886, 2005.
- [23] R. Yagi, D. McBurney, D. Lavery, S. Weiner, and W. E. Horton Jr., "Intra joint comparisons of gene expression patterns in human osteoarthritis suggest a change in chondrocyte phenotype," *Journal of Orthopaedic Research*, vol. 23, no. 5, pp. 1128–1138, 2005.
- [24] R. Terkeltaub, M. Lotz, K. Johnson et al., "Parathyroid hormone-related protein is abundant in osteoarthritic cartilage, and the parathyroid hormone-related protein 1-173 isoform is selectively induced by transforming growth factor β in articular chondrocytes and suppresses generation of extracellular inorganic pyrophosphate," *Arthritis and Rheumatism*, vol. 41, no. 12, pp. 2152–2164, 1998.
- [25] K. von der Mark, T. Kirsch, A. Nerlich et al., "Type X collagen synthesis in human osteoarthritic cartilage: indication of chondrocyte hypertrophy," *Arthritis and Rheumatism*, vol. 35, no. 7, pp. 806–811, 1992.
- [26] I. Girkontaite, S. Frischholz, P. Lammi et al., "Immunolocalization of type X collagen in normal fetal and adult

- osteoarthritic cartilage with monoclonal antibodies," *Matrix Biology*, vol. 15, no. 4, pp. 231–238, 1996.
- [27] G. D. Walker, M. Fischer, J. Gannon, R. C. Thompson, and T. R. Oegema, "Expression of type-X collagen in osteoarthritis," *Journal of Orthopaedic Research*, vol. 13, no. 1, pp. 4–12, 1995.
 - [28] T. Kirsch, B. Swoboda, and H. D. Nah, "Activation of annexin II and V expression, terminal differentiation, mineralization and apoptosis in human osteoarthritic cartilage," *Osteoarthritis and Cartilage*, vol. 8, no. 4, pp. 294–302, 2000.
 - [29] D. Pfander, T. Cramer, E. Schipani, and R. S. Johnson, "HIF-1 α controls extracellular matrix synthesis by epiphyseal chondrocytes," *Journal of Cell Science*, vol. 116, no. 9, pp. 1819–1826, 2003.
 - [30] O. Pullig, G. Weseloh, D. L. Ronneberger, S. M. Kknen, and B. Swoboda, "Chondrocyte differentiation in human osteoarthritis: expression of osteocalcin in normal and osteoarthritic cartilage and bone," *Calcified Tissue International*, vol. 67, no. 3, pp. 230–240, 2000.
 - [31] G. A. Karpouzas and R. A. Terkeltaub, "New developments in the pathogenesis of articular cartilage calcification," *Current Rheumatology Reports*, vol. 1, no. 2, pp. 121–127, 1999.
 - [32] K. Johnson and R. Terkeltaub, "Upregulated ank expression in osteoarthritis can promote both chondrocyte MMP-13 expression and calcification via chondrocyte extracellular PPI excess," *Osteoarthritis and Cartilage*, vol. 12, no. 4, pp. 321–335, 2004.
 - [33] F. J. Blanco, R. Guitian, E. Vzquez-Martul, F. J. de Toro, and F. Galdo, "Osteoarthritis chondrocytes die by apoptosis: a possible pathway for osteoarthritis pathology," *Arthritis and Rheumatism*, vol. 41, no. 2, pp. 284–289, 1998.
 - [34] C. M. Robertson, A. T. Pennock, F. L. Harwood, A. C. Pomerleau, R. T. Allen, and D. Amiel, "Characterization of pro-apoptotic and matrix-degradative gene expression following induction of osteoarthritis in mature and aged rabbits," *Osteoarthritis and Cartilage*, vol. 14, no. 5, pp. 471–476, 2006.
 - [35] E. Tchetina, F. Mwale, and A. R. Poole, "Distinct phases of coordinated early and late gene expression in growth plate chondrocytes in relationship to cell proliferation, matrix assembly, remodeling, and cell differentiation," *Journal of Bone and Mineral Research*, vol. 18, no. 5, pp. 844–851, 2003.
 - [36] A. V. Ham and D. H. Cormack, *Ham's Histology*, Lippincott, Philadelphia, Pa, USA, 1987.
 - [37] S. Yamane, E. Cheng, Z. You, and A. H. Reddi, "Gene expression profiling of mouse articular and growth plate cartilage," *Tissue Engineering*, vol. 13, no. 9, pp. 2163–2173, 2007.
 - [38] P. Krejci, D. Krakow, P. B. Mekikian, and W. R. Wilcox, "Fibroblast growth factors 1, 2, 17, and 19 are the predominant FGF ligands expressed in human fetal growth plate cartilage," *Pediatric Research*, vol. 61, no. 3, pp. 267–272, 2007.
 - [39] O. Nilsson, E. A. Parker, A. Hegde, M. Chau, K. M. Barnes, and J. Baron, "Gradients in bone morphogenetic protein-related gene expression across the growth plate," *Journal of Endocrinology*, vol. 193, no. 1, pp. 75–84, 2007.
 - [40] H. C. Anderson, P. T. Hodges, X. M. Aguilera, L. Missana, and P. E. Moylan, "Bone morphogenetic protein (BMP) localization in developing human and rat growth plate, metaphysis, epiphysis, and articular cartilage," *Journal of Histochemistry and Cytochemistry*, vol. 48, no. 11, pp. 1493–1502, 2000.
 - [41] S. Matsunaga, T. Yamamoto, and K. Fukumura, "Temporal and spatial expressions of transforming growth factor- β s and their receptors in epiphyseal growth plate," *International Journal of Oncology*, vol. 14, no. 6, pp. 1063–1067, 1999.
 - [42] T. A. Damron, S. Mathur, J. A. Horton et al., "Temporal changes in PTHrP, Bcl-2, Bax, caspase, TGF- β , and FGF-2 expression following growth plate irradiation with or without radioprotectant," *Journal of Histochemistry and Cytochemistry*, vol. 52, no. 2, pp. 157–167, 2004.
 - [43] M. P. Verdier, S. Seit, K. Guntzer, J. P. Pujol, and K. Boumdine, "Immunohistochemical analysis of transforming growth factor beta isoforms and their receptors in human cartilage from normal and osteoarthritic femoral heads," *Rheumatology International*, vol. 25, no. 2, pp. 118–124, 2005.
 - [44] F. Beier, Z. Ali, D. Mok et al., "TGF β and PTHrP control chondrocyte proliferation by activating cyclin D1 expression," *Molecular Biology of the Cell*, vol. 12, no. 12, pp. 3852–3863, 2001.
 - [45] H. I. Roach, G. Mehta, R. O. C. Oreffo, N. M. P. Clarke, and C. Cooper, "Temporal analysis of rat growth plates: cessation of growth with age despite presence of a physis," *Journal of Histochemistry and Cytochemistry*, vol. 51, no. 3, pp. 373–383, 2003.
 - [46] F. Mwale, C. Billingham, W. Wu et al., "Selective assembly and remodelling of collagens II and IX associated with expression of the chondrocyte hypertrophic phenotype," *Developmental Dynamics*, vol. 218, no. 4, pp. 648–662, 2000.
 - [47] L. A. Neuhold, L. Killar, W. Zhao et al., "Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice," *Journal of Clinical Investigation*, vol. 107, no. 1, pp. 35–44, 2001.
 - [48] A. L. Armstrong, H. J. Barrach, and M. G. Ehrlich, "Identification of the metalloproteinase stromelysin in the physis," *Journal of Orthopaedic Research*, vol. 20, no. 2, pp. 289–294, 2002.
 - [49] F. H. Wezeman and M. R. Bollnow, "Immunohistochemical localization of fibroblast growth factor-2 in normal and brachymorphic mouse tibial growth plate and articular cartilage," *Histochemical Journal*, vol. 29, no. 6, pp. 505–514, 1997.
 - [50] A. Horner, P. Kemp, C. Summers et al., "Expression and distribution of transforming growth factor- β isoforms and their signaling receptors in growing human bone," *Bone*, vol. 23, no. 2, pp. 95–102, 1998.
 - [51] Y. Wang, S. Nishida, T. Sakata et al., "Insulin-like growth factor-I is essential for embryonic bone development," *Endocrinology*, vol. 147, no. 10, pp. 4753–4761, 2006.
 - [52] P. de los Rios and D. J. Hill, "Cellular localization and expression of insulin-like growth factors (IGFs) and IGF binding proteins within the epiphyseal growth plate of the ovine fetus: possible functional implications," *Canadian Journal of Physiology and Pharmacology*, vol. 77, no. 4, pp. 235–249, 1999.
 - [53] D. M. Shinar, N. Endo, D. Halperin, G. A. Rodan, and M. Weinreb, "Differential expression of insulin-like growth factor-I (IGF-I) and IGF-II messenger ribonucleic acid in growing rat bone," *Endocrinology*, vol. 132, no. 3, pp. 1158–1167, 1993.
 - [54] Q. Ma, X. Li, D. Vale-Cruz, M. L. Brown, F. Beier, and P. LuValle, "Activating transcription factor 2 controls Bcl-2 promoter activity in growth plate chondrocytes," *Journal of Cellular Biochemistry*, vol. 101, no. 2, pp. 477–487, 2007.
 - [55] H. Akiyama, M. C. Chaboissier, J. F. Martin, A. Schedl, and B. de Crombrughe, "The transcription factor Sox9 has essential roles in successive steps of the chondrocyte

- differentiation pathway and is required for expression of Sox5 and Sox6," *Genes and Development*, vol. 16, no. 21, pp. 2813–2828, 2002.
- [56] D. W. Burton, M. Foster, K. A. Johnson, M. Hiramoto, L. J. Deftos, and R. Terkeltaub, "Chondrocyte calcium-sensing receptor expression is up-regulated in early guinea pig knee osteoarthritis and modulates PTHrP, MMP-13, and TIMP-3 expression," *Osteoarthritis Cartilage*, vol. 13, no. 5, pp. 395–404, 2005.
 - [57] J. A. Uriá, M. Balbín, J. M. López et al., "Collagenase-3 (MMP-13) expression in chondrosarcoma cells and its regulation by basic fibroblast growth factor," *American Journal of Pathology*, vol. 153, no. 1, pp. 91–101, 1998.
 - [58] P. Borden, D. Solymar, A. Sucharczuk, B. Lindman, P. Cannon, and R. A. Heller, "Cytokine control of interstitial collagenase and collagenase-3 gene expression in human chondrocytes," *Journal of Biological Chemistry*, vol. 271, no. 38, pp. 23577–23581, 1996.
 - [59] G. Haeusler, I. Walter, M. Helmreich, and M. Egerbacher, "Localization of matrix metalloproteinases (MMPs) their tissue inhibitors, and vascular endothelial growth factor (VEGF) in growth plates of children and adolescents indicates a role for MMPs in human postnatal growth and skeletal maturation," *Calcified Tissue International*, vol. 76, no. 5, pp. 326–335, 2005.
 - [60] C. Li, L. Chen, T. Iwata, M. Kitagawa, X. Y. Fu, and C. X. Deng, "A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors," *Human Molecular Genetics*, vol. 8, no. 1, pp. 35–44, 1999.
 - [61] K. Tsuchimochi, M. Otero, C. L. Dragomir et al., "GADD45 β enhances Col10a1 transcription via the MTK1/MKK3/6/p38 axis and activation of C/EBP β -TAD4 in terminally differentiating chondrocytes," *Journal of Biological Chemistry*, vol. 285, no. 11, pp. 8395–8407, 2010.
 - [62] K. Ijiri, L. F. Zerbini, H. Peng et al., "A novel role for GADD45 β as a mediator of MMP-13 gene expression during chondrocyte terminal differentiation," *Journal of Biological Chemistry*, vol. 280, no. 46, pp. 38544–38555, 2005.
 - [63] M. D. Kinkel, R. Yagi, D. McBurney, A. Nugent, and W. E. Horton Jr., "Age-related expression patterns of Bag-1 and Bcl-2 in growth plate and articular chondrocytes," *Anatomical Record Part A*, vol. 279, no. 2, pp. 720–728, 2004.
 - [64] J. P. Tuckermann, K. Pittois, N. C. Partridge, J. Merregaert, and P. Angel, "Collagenase-3 (MMP-13) and integral membrane protein 2a (Itm2a) are marker genes of chondrogenic/osteoblastic cells in bone formation: sequential temporal, and spatial expression of Itm2a, alkaline phosphatase, MMP-13, and osteocalcin in the mouse," *Journal of Bone and Mineral Research*, vol. 15, no. 7, pp. 1257–1265, 2000.
 - [65] F. M. D. Henson, M. E. Davies, J. N. Skepper, and L. B. Jeffcott, "Localisation of alkaline phosphatase in equine growth cartilage," *Journal of Anatomy*, vol. 187, no. 1, pp. 151–159, 1995.
 - [66] R. Pogue and K. Lyons, "BMP signaling in the cartilage growth plate," *Current Topics in Developmental Biology*, vol. 76, pp. 1–48, 2006.
 - [67] Y. Wang, F. Middleton, J. A. Horton, L. Reichel, C. E. Farnum, and T. A. Damron, "Microarray analysis of proliferative and hypertrophic growth plate zones identifies differentiation markers and signal pathways," *Bone*, vol. 35, no. 6, pp. 1273–1293, 2004.
 - [68] T. Sakou, T. Onishi, T. Yamamoto, T. Nagamine, T. K. Sampath, and P. Ten Dijke, "Localization of Smads, the TGF- β family intracellular signaling components during endochondral ossification," *Journal of Bone and Mineral Research*, vol. 14, no. 7, pp. 1145–1152, 1999.
 - [69] T. Fukunaga, T. Yamashiro, S. Oya, N. Takeshita, M. Takigawa, and T. Takano-Yamamoto, "Connective tissue growth factor mRNA expression pattern in cartilages is associated with their type I collagen expression," *Bone*, vol. 33, no. 6, pp. 911–918, 2003.
 - [70] J. Álvarez, L. Costales, R. Serra, M. Balbín, and J. M. López, "Expression patterns of matrix metalloproteinases and vascular endothelial growth factor during epiphyseal ossification," *Journal of Bone and Mineral Research*, vol. 20, no. 6, pp. 1011–1021, 2005.
 - [71] H. E. MacLean and H. M. Kronenberg, "Localization of Indian hedgehog and PTH/PTHrP receptor expression in relation to chondrocyte proliferation during mouse bone development," *Development Growth and Differentiation*, vol. 47, no. 2, pp. 59–63, 2005.
 - [72] J. M. Kindblom, O. Nilsson, T. Hurme, C. Ohlsson, and L. Sävdahl, "Expression and localization of Indian hedgehog (Ihh) and parathyroid hormone related protein (PTHrP) in the human growth plate during pubertal development," *Journal of Endocrinology*, vol. 174, no. 2, pp. R1–R6, 2002.
 - [73] F. Yamashita, K. Sakakida, K. Kusuzaki, H. Takeshita, and A. Kuzuhara, "Immunohistochemical localization of interleukin 1 in human growth cartilage," *Nippon Seikeigeka Gakkai Zasshi*, vol. 63, no. 5, pp. 562–568, 1989.
 - [74] P. Ducy, R. Zhang, V. Geoffroy, A. L. Ridall, and G. Karsenty, "Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation," *Cell*, vol. 89, no. 5, pp. 747–754, 1997.
 - [75] P. M. van der Kraan, E. N. Blaney Davidson, A. Blom, and W. B. van den Berg, "TGF-beta signaling in chondrocyte terminal differentiation and osteoarthritis. Modulation and integration of signaling pathways through receptor-Smads," *Osteoarthritis and Cartilage*, vol. 17, no. 12, pp. 1539–1545, 2009.
 - [76] T. Komori, "A fundamental transcription factor for bone and cartilage," *Biochemical and Biophysical Research Communications*, vol. 276, no. 3, pp. 813–816, 2000.
 - [77] S. Takeda, J. P. Bonnamy, M. J. Owen, P. Ducy, and G. Karsenty, "Continuous expression of Cbfa1 in nonhypertrophic chondrocytes uncovers its ability to induce hypertrophic chondrocyte differentiation and partially rescues Cbfa1-deficient mice," *Genes and Development*, vol. 15, no. 4, pp. 467–481, 2001.
 - [78] C. Ueta, M. Iwamoto, N. Kanatani et al., "Skeletal malformations caused by overexpression of Cbfa1 or its dominant negative form in chondrocytes," *Journal of Cell Biology*, vol. 153, no. 1, pp. 87–99, 2001.
 - [79] D. Porte, J. Tuckermann, M. Becker et al., "Both AP-1 and Cbfa1-like factors are required for the induction of interstitial collagenase by parathyroid hormone," *Oncogene*, vol. 18, no. 3, pp. 667–678, 1999.
 - [80] M. J. G. Jiménez, M. Balbín, J. M. López, J. Alvarez, T. Komori, and C. López-Otín, "Collagenase 3 is a target of Cbfa1, a transcription factor of the runt gene family involved in bone formation," *Molecular and Cellular Biology*, vol. 19, no. 6, pp. 4431–4442, 1999.
 - [81] F. Mwale, E. Tchetina, C. W. Wu, and A. R. Poole, "The assembly and remodeling of the extracellular matrix in the growth plate in relationship to mineral deposition and cellular hypertrophy: an in situ study of collagens II and IX and proteoglycan," *Journal of Bone and Mineral Research*, vol. 17, no. 2, pp. 275–283, 2002.

- [82] W. Wang, J. Xu, B. Du, and T. Kirsch, "Role of the progressive ankylosis gene (ank) in cartilage mineralization," *Molecular and Cellular Biology*, vol. 25, no. 1, pp. 312–323, 2005.
- [83] W. Wang, J. Xu, and T. Kirsch, "Annexin-mediated Ca^{2+} influx regulates growth plate chondrocyte maturation and apoptosis," *Journal of Biological Chemistry*, vol. 278, no. 6, pp. 3762–3769, 2003.
- [84] T. Kirsch, "Annexins—their role in cartilage mineralization," *Frontiers in Bioscience*, vol. 10, pp. 576–581, 2005.
- [85] W. Wang, J. Xu, and T. Kirsch, "Annexin V and terminal differentiation of growth plate chondrocytes," *Experimental Cell Research*, vol. 305, no. 1, pp. 156–165, 2005.
- [86] R. K. Gill, R. T. Turner, T. J. Wronski, and N. H. Bell, "Orchiectomy markedly reduces the concentration of the three isoforms of transforming growth factor β in rat bone, and reduction is prevented by testosterone," *Endocrinology*, vol. 139, no. 2, pp. 546–550, 1998.
- [87] I. M. Shapiro, C. S. Adams, T. Freeman, and V. Srinivas, "Fate of the hypertrophic chondrocyte: microenvironmental perspectives on apoptosis and survival in the epiphyseal growth plate," *Birth Defects Research Part C*, vol. 75, no. 4, pp. 330–339, 2005.
- [88] R. C. Olney, J. Wang, J. E. Sylvester, and E. B. Mougey, "Growth factor regulation of human growth plate chondrocyte proliferation in vitro," *Biochemical and Biophysical Research Communications*, vol. 317, no. 4, pp. 1171–1182, 2004.
- [89] M. R. Hutchison, M. H. Bassett, and P. C. White, "Insulin-like growth factor-I and fibroblast growth factor, but not growth hormone, affect growth plate chondrocyte proliferation," *Endocrinology*, vol. 148, no. 7, pp. 3122–3130, 2007.
- [90] H. M. Kronenberg, "PTHrP and skeletal development," *Annals of the New York Academy of Sciences*, vol. 1068, no. 1, pp. 1–13, 2006.
- [91] T. F. Li, Y. Dong, A. M. Ionescu et al., "Parathyroid hormone-related peptide (PTHrP) inhibits Runx2 expression through the PKA signaling pathway," *Experimental Cell Research*, vol. 299, no. 1, pp. 128–136, 2004.
- [92] Y. F. Dong, Y. Soung do, E. M. Schwarz, R. J. O'Keefe, and H. Drissi, "Wnt induction of chondrocyte hypertrophy through the Runx2 transcription factor," *Journal of Cellular Physiology*, vol. 208, no. 1, pp. 77–86, 2006.
- [93] D. Kiepe, S. Ciarmatori, A. Haarmann, and B. Tönshoff, "Differential expression of IGF system components in proliferating vs. differentiating growth plate chondrocytes: the functional role of IGFBP-5," *American Journal of Physiology*, vol. 290, no. 2, pp. E363–E371, 2006.
- [94] A. C. Karaplis, A. Luz, J. Glowacki et al., "Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene," *Genes and Development*, vol. 8, no. 3, pp. 277–289, 1994.
- [95] N. Amizuka, H. Warshawsky, J. E. Henderson, D. Goltzman, and A. C. Karaplis, "Parathyroid hormone-related peptide-depleted mice show abnormal epiphyseal cartilage development and altered endochondral bone formation," *Journal of Cell Biology*, vol. 126, no. 6, pp. 1611–1623, 1994.
- [96] E. C. Weir, W. M. Philbrick, M. Amling, L. A. Neff, R. Baron, and A. E. Broadus, "Targeted overexpression of parathyroid hormone-related peptide in chondrocytes causes chondrodysplasia and delayed endochondral bone formation," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 93, no. 19, pp. 10240–10245, 1996.
- [97] B. Lanske, A. C. Karaplis, K. Lee et al., "PTH/PTHrP receptor in early development and Indian hedgehog-regulated bone growth," *Science*, vol. 273, no. 5275, pp. 663–666, 1996.
- [98] A. Vortkamp, K. Lee, B. Lanske, G. V. Segre, H. M. Kronenberg, and C. J. Tabin, "Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein," *Science*, vol. 273, no. 5275, pp. 613–622, 1996.
- [99] E. Yoshida, M. Noshiro, T. Kawamoto, S. Tsutsumi, Y. Kuruta, and Y. Kato, "Direct inhibition of Indian hedgehog expression by parathyroid hormone (PTH)/PTH-related peptide and up-regulation by retinoic acid in growth plate chondrocyte cultures," *Experimental Cell Research*, vol. 265, no. 1, pp. 64–72, 2001.
- [100] B. St-Jacques, M. Hammerschmidt, and A. P. McMahon, "Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation," *Genes and Development*, vol. 13, no. 16, pp. 2072–2086, 1999.
- [101] M. Pacifici, T. Shimo, C. Gentili et al., "Syndecan-3: a cell-surface heparan sulfate proteoglycan important for chondrocyte proliferation and function during limb skeletogenesis," *Journal of Bone and Mineral Metabolism*, vol. 23, no. 3, pp. 191–199, 2005.
- [102] A. B. Roberts and M. B. Sporn, "Physiological actions and clinical applications of transforming growth factor- β (TGF- β)," *Growth Factors*, vol. 8, no. 1, pp. 1–9, 1993.
- [103] G. Gibson, "Active role of chondrocyte apoptosis in endochondral ossification," *Microscopy Research and Technique*, vol. 43, no. 2, pp. 191–204, 1998.
- [104] X. Yang, L. Chen, X. Xu, C. Li, C. Huang, and C. X. Deng, "TGF- β /Smad3 signals repress chondrocyte hypertrophic differentiation and are required for maintaining articular cartilage," *Journal of Cell Biology*, vol. 153, no. 1, pp. 35–46, 2001.
- [105] R. Serra, A. Karaplis, and P. Sohn, "Parathyroid hormone-related peptide (PTHrP)-dependent and -independent effects of transforming growth factor β (TGF- β) on endochondral bone formation," *Journal of Cell Biology*, vol. 145, no. 4, pp. 783–794, 1999.
- [106] C. M. Ferguson, E. M. Schwarz, P. R. Reynolds, J. E. Puzas, R. N. Rosier, and R. J. O'Keefe, "Smad2 and 3 mediate transforming growth factor- β 1-induced inhibition of chondrocyte maturation," *Endocrinology*, vol. 141, no. 12, pp. 4728–4735, 2000.
- [107] R. T. Ballock, A. Heydemann, L. M. Wakefield, K. C. Flanders, A. B. Roberts, and M. B. Sporn, "TGF- β 1 prevents hypertrophy of epiphyseal chondrocytes: regulation of gene expression for cartilage matrix proteins and metalloproteases," *Developmental Biology*, vol. 158, no. 2, pp. 414–429, 1993.
- [108] K. Bohme, K. H. Winterhhlter, and P. Bruckner, "Terminal differentiation of chondrocytes in culture is a spontaneous process and is arrested by transforming growth factor- β 2 and basic fibroblast growth factor in synergy," *Experimental Cell Research*, vol. 216, no. 1, pp. 191–198, 1995.
- [109] R. A. Terkeltaub, K. Johnson, D. Rohnow, R. Goomer, D. Burton, and L. J. Deftos, "Bone morphogenetic proteins and bFGF exert opposing regulatory effects on PTHrP expression and inorganic pyrophosphate elaboration in immortalized murine endochondral hypertrophic chondrocytes (MCT cells)," *Journal of Bone and Mineral Research*, vol. 13, no. 6, pp. 931–941, 1998.

- [110] D. B. Paderer, R. N. Rosier, E. M. Schwarz et al., "PTHrP expression in chondrocytes, regulation by TGF- β , and interactions between epiphyseal and growth plate chondrocytes," *Experimental Cell Research*, vol. 256, no. 2, pp. 555–562, 2000.
- [111] H. Nagai and M. Aoki, "Inhibition of growth plate angiogenesis and endochondral ossification with diminished expression of MMP-13 in hypertrophic chondrocytes in FGF-2-treated rats," *Journal of Bone and Mineral Metabolism*, vol. 20, no. 3, pp. 142–147, 2002.
- [112] V. Szuts, U. Möllers, K. Bittner et al., "Terminal differentiation of chondrocytes is arrested at distinct stages identified by their expression repertoire of marker genes," *Matrix Biology*, vol. 17, no. 6, pp. 435–448, 1998.
- [113] Q. Wang, X. Wei, T. Zhu et al., "Bone morphogenetic protein 2 activates Smad6 gene transcription through bone-specific transcription factor Runx2," *Journal of Biological Chemistry*, vol. 282, no. 14, pp. 10742–10748, 2007.
- [114] T. Kobayashi, K. M. Lyons, A. P. McMahon, and H. M. Kronenberg, "BMP signaling stimulates cellular differentiation at multiple steps during cartilage development," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 50, pp. 18023–18027, 2005.
- [115] B. S. Yoon, R. Pogue, D. A. Ovchinnikov et al., "BMPs regulate multiple aspects of growth-plate chondrogenesis through opposing actions on FGF pathways," *Development*, vol. 133, no. 23, pp. 4667–4678, 2006.
- [116] M. C. Stewart, R. M. Kadlec, P. D. Robbins, J. N. Macleod, and R. T. Ballock, "Expression and activity of the CDK inhibitor p57^{Kip2} in chondrocytes undergoing hypertrophic differentiation," *Journal of Bone and Mineral Research*, vol. 19, no. 1, pp. 123–132, 2004.
- [117] D. Zhang, E. M. Schwarz, R. N. Rosier, M. J. Zuscik, J. E. Puzas, and R. J. O'Keefe, "ALK2 functions as a BMP type I receptor and induces Indian hedgehog in chondrocytes during skeletal development," *Journal of Bone and Mineral Research*, vol. 18, no. 9, pp. 1593–1604, 2003.
- [118] C. D. Grimsrud, P. R. Romano, M. D'Souza et al., "BMP-6 is an autocrine stimulator of chondrocyte differentiation," *Journal of Bone and Mineral Research*, vol. 14, no. 4, pp. 475–482, 1999.
- [119] T. Takahashi, E. A. Morris, and S. B. Trippel, "Bone morphogenetic protein-2 and -9 regulate the interaction of insulin-like growth factor-I with growth plate chondrocytes," *International Journal of Molecular Medicine*, vol. 20, no. 1, pp. 53–57, 2007.
- [120] G. Mailhot, M. Yang, A. Mason-Savas, C. A. Mackay, I. Leav, and P. R. Odgren, "BMP-5 expression increases during chondrocyte differentiation in vivo and in vitro and promotes proliferation and cartilage matrix synthesis in primary chondrocyte cultures," *Journal of Cellular Physiology*, vol. 214, no. 1, pp. 56–64, 2008.
- [121] Z. Laron, "Insulin-like growth factor 1 (IGF-1): a growth hormone," *Molecular Pathology*, vol. 54, no. 5, pp. 311–316, 2001.
- [122] W. Hui, A. D. Rowan, and T. Cawston, "Insulin-like growth factor 1 blocks collagen release and down regulates matrix metalloproteinase-1, -3, -8, and -13 mRNA expression in bovine nasal cartilage stimulated with oncostatin M in combination with interleukin 1 α ," *Annals of the Rheumatic Diseases*, vol. 60, no. 3, pp. 254–261, 2001.
- [123] V. Lefebvre and P. Smits, "Transcriptional control of chondrocyte fate and differentiation," *Birth Defects Research Part C*, vol. 75, no. 3, pp. 200–212, 2005.
- [124] T. Hattori, C. Müller, S. Gebhard et al., "SOX9 is a major negative regulator of cartilage vascularization, bone marrow formation and endochondral ossification," *Development*, vol. 137, no. 6, pp. 901–911, 2010.
- [125] M. Wuelling and A. Vortkamp, "Transcriptional networks controlling chondrocyte proliferation and differentiation during endochondral ossification," *Pediatric Nephrology*, vol. 25, no. 4, pp. 625–631, 2010.
- [126] Q. Zhao, H. Eberspaecher, V. Lefebvre, and B. de Crombrughe, "Parallel expression of Sox9 and Col2a1 in cells undergoing chondrogenesis," *Developmental Dynamics*, vol. 209, no. 4, pp. 377–386, 1997.
- [127] B. de Crombrughe, V. Lefebvre, R. R. Behringer, W. Bi, S. Murakami, and W. Huang, "Transcriptional mechanisms of chondrocyte differentiation," *Matrix Biology*, vol. 19, no. 5, pp. 389–394, 2000.
- [128] L. J. Ng, S. Wheatley, G. E. O. Muscat et al., "SOX9 binds DNA, activates transcription, and coexpresses with type II collagen during chondrogenesis in the mouse," *Developmental Biology*, vol. 183, no. 1, pp. 108–121, 1997.
- [129] W. Bi, W. Huang, D. J. Whitworth et al., "Haploinsufficiency of Sox9 results in defective cartilage primordia and premature skeletal mineralization," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 12, pp. 6698–6703, 2001.
- [130] S. Reppe, E. Rian, R. Jemtland, O. K. Olstad, V. T. Gautvik, and K. M. Gautvik, "Sox-4 messenger RNA is expressed in the embryonic growth plate and regulated via the parathyroid hormone/parathyroid hormone-related protein receptor in osteoblast-like cells," *Journal of Bone and Mineral Research*, vol. 15, no. 12, pp. 2402–2412, 2000.
- [131] Y. Soung do, Y. Dong, Y. Wang et al., "Runx3/AML2/Cbfa3 regulates early and late chondrocyte differentiation," *Journal of Bone and Mineral Research*, vol. 22, no. 8, pp. 1260–1270, 2007.
- [132] L. A. Solomon, N. G. Bérubé, and F. Beier, "Transcriptional regulators of chondrocyte hypertrophy," *Birth Defects Research Part C*, vol. 84, no. 2, pp. 123–130, 2008.
- [133] H. Drissi, M. Zuscik, R. Rosier, and R. O'Keefe, "Transcriptional regulation of chondrocyte maturation: potential involvement of transcription factors in OA pathogenesis," *Molecular Aspects of Medicine*, vol. 26, no. 3, pp. 169–179, 2005.
- [134] T. F. Li, M. J. Zuscik, A. M. Ionescu et al., "PGE₂ inhibits chondrocyte differentiation through PKA and PKC signaling," *Experimental Cell Research*, vol. 300, no. 1, pp. 159–169, 2004.
- [135] X. Zhang, N. Ziran, J. J. Goater et al., "Primary murine limb bud mesenchymal cells in long-term culture complete chondrocyte differentiation: TGF- β delays hypertrophy and PGE₂ inhibits terminal differentiation," *Bone*, vol. 34, no. 5, pp. 809–817, 2004.
- [136] Z. Schwartz, R. M. Gilley, V. L. Sylvia, D. D. Dean, and B. D. Boyan, "The effect of prostaglandin E₂ on costochondral chondrocyte differentiation is mediated by cyclic adenosine 3',5'-monophosphate and protein kinase C," *Endocrinology*, vol. 139, no. 4, pp. 1825–1834, 1998.
- [137] C. Brochhausen, P. Neuland, C. J. Kirkpatrick, R. M. Nüsing, and G. Klaus, "Cyclooxygenases and prostaglandin E₂ receptors in growth plate chondrocytes in vitro and in situ—prostaglandin E₂ dependent proliferation of growth plate chondrocytes," *Arthritis Research & Therapy*, vol. 8, no. 3, article R78, 2006.

- [138] L. Wei, K. Kanbe, M. Lee et al., "Stimulation of chondrocyte hypertrophy by chemokine stromal cell-derived factor 1 in the chondro-osseous junction during endochondral bone formation," *Developmental Biology*, vol. 341, no. 1, pp. 236–245, 2010.
- [139] W. Wang and T. Kirsch, "Annexin V/ $\beta 5$ integrin interactions regulate apoptosis of growth plate chondrocytes," *Journal of Biological Chemistry*, vol. 281, no. 41, pp. 30848–30856, 2006.
- [140] M. S. Domowicz, M. Cortes, J. G. Henry, and N. B. Schwartz, "Aggrecan modulation of growth plate morphogenesis," *Developmental Biology*, vol. 329, no. 2, pp. 242–257, 2009.
- [141] L. van der Weyden, L. Wei, J. Luo et al., "Functional knockout of the matrilin-3 gene causes premature chondrocyte maturation to hypertrophy and increases bone mineral density and osteoarthritis," *American Journal of Pathology*, vol. 169, no. 2, pp. 515–527, 2006.
- [142] O. Barbieri, S. Astigiano, M. Morini et al., "Depletion of cartilage collagen fibrils in mice carrying a dominant negative Col2a1 transgene affects chondrocyte differentiation," *American Journal of Physiology*, vol. 285, no. 6, pp. C1504–C1512, 2003.
- [143] R. M. Borzi, E. Olivetto, S. Pagani et al., "Matrix metalloproteinase 13 loss associated with impaired extracellular matrix remodeling disrupts chondrocyte differentiation by concerted effects on multiple regulatory factors," *Arthritis and Rheumatism*, vol. 62, no. 8, pp. 2370–2381, 2010.
- [144] C. J. Malemud, "Matrix metalloproteinases: role in skeletal development and growth plate disorders," *Frontiers in Bioscience*, vol. 11, no. 2, pp. 1702–1715, 2006.
- [145] Q. Chen, D. M. Johnson, D. R. Haudenschild, and P. F. Goetinck, "Progression and recapitulation of the chondrocyte differentiation program: cartilage matrix protein is a marker for cartilage maturation," *Developmental Biology*, vol. 172, no. 1, pp. 293–306, 1995.
- [146] J. A. Buckwalter and H. J. Mankin, "Articular cartilage repair and transplantation," *Arthritis and Rheumatism*, vol. 41, no. 8, pp. 1331–1342, 1998.
- [147] T. E. Hardingham, A. J. Fosang, and J. Dudhia, "Aggrecan, the chondroitin sulfate/keratan sulfate proteoglycan from cartilage," in *Articular Cartilage and Osteoarthritis*, K. Kuettner et al., Ed., Raven Press, New York, NY, USA, 1992.
- [148] T. Aigner, A. Zien, D. Hanisch, and R. Zimmer, "Gene expression in chondrocytes assessed with use of microarrays," *Journal of Bone and Joint Surgery. American*, vol. 85, no. 1, pp. 117–123, 2003.
- [149] L. C. Tetlow, D. J. Adlam, and D. E. Woolley, "Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes," *Arthritis and Rheumatism*, vol. 44, no. 3, pp. 585–594, 2001.
- [150] W. B. van den Berg, "Growth factors in experimental osteoarthritis: transforming growth factor β pathogenic?" *Journal of Rheumatology*, vol. 22, no. 43, pp. 143–145, 1995.
- [151] X. Chen, C. M. Macica, A. Nasiri, and A. E. Broadus, "Regulation of articular chondrocyte proliferation and differentiation by Indian hedgehog and parathyroid hormone-related protein in mice," *Arthritis and Rheumatism*, vol. 58, no. 12, pp. 3788–3797, 2008.
- [152] Y. Hiraki, H. Inoue, K. I. Iyama et al., "Identification of chondromodulin I as a novel endothelial cell growth inhibitor: purification and its localization in the avascular zone of epiphyseal cartilage," *Journal of Biological Chemistry*, vol. 272, no. 51, pp. 32419–32426, 1997.
- [153] H. Kitahara, T. Hayami, K. Tokunaga et al., "Chondromodulin-I expression in rat articular cartilage," *Archives of Histology and Cytology*, vol. 66, no. 3, pp. 221–228, 2003.
- [154] K. Ijiri, L. F. Zerbini, H. Peng et al., "Differential expression of GADD45 β in normal and osteoarthritic cartilage: potential role in homeostasis of articular chondrocytes," *Arthritis and Rheumatism*, vol. 58, no. 7, pp. 2075–2087, 2008.
- [155] H. W. Zhou, S. Q. Lou, and K. Zhang, "Recovery of function in osteoarthritic chondrocytes induced by p16INK4a-specific siRNA in vitro," *Rheumatology*, vol. 43, pp. 555–568, 2004.
- [156] T. Aigner and L. McKenna, "Molecular pathology and pathobiology of osteoarthritic cartilage," *Cellular and Molecular Life Sciences*, vol. 59, no. 1, pp. 5–18, 2002.
- [157] A. R. Poole, "What type of cartilage repair are we attempting to attain?" *Journal of Bone and Joint Surgery. American*, vol. 85, no. 1, pp. 40–44, 2003.
- [158] A. Scharstuhl, H. L. Glansbeek, H. M. van Beuningen, E. L. Vitters, P. M. van der Kraan, and W. B. van den Berg, "Inhibition of endogenous TGF- β during experimental osteoarthritis prevents osteophyte formation and impairs cartilage repair," *Journal of Immunology*, vol. 169, no. 1, pp. 507–514, 2002.
- [159] P. K. Bos, G. J. V. M. van Osch, D. A. Frenz, J. A. N. Verhaar, and H. L. Verwoerd-Verhoef, "Growth factor expression in cartilage wound healing: temporal and spatial immunolocalization in a rabbit auricular cartilage wound model," *Osteoarthritis and Cartilage*, vol. 9, no. 4, pp. 382–389, 2001.
- [160] A. H. White, R. E. B. Watson, B. Newman, A. J. Freemont, and G. A. Wallis, "Annexin VIII is differentially expressed by chondrocytes in the mammalian growth plate during endochondral ossification and in osteoarthritic cartilage," *Journal of Bone and Mineral Research*, vol. 17, no. 10, pp. 1851–1858, 2002.
- [161] G. E. Kempson, H. Muir, C. Pollard, and M. Tuke, "The tensile properties of the cartilage of human femoral condyles related to the content of collagen and glycosaminoglycans," *Biochimica et Biophysica Acta*, vol. 297, no. 2, pp. 456–472, 1973.
- [162] A. R. Poole, L. C. Rosenberg, A. Reiner, M. Ionescu, E. Bogoch, and P. J. Roughley, "Contents and distributions of the proteoglycans decorin and biglycan in normal and osteoarthritic human articular cartilage," *Journal of Orthopaedic Research*, vol. 14, no. 5, pp. 681–689, 1996.
- [163] D. Pfander, B. Swoboda, and T. Kirsch, "Expression of early and late differentiation markers (proliferating cell nuclear antigen, syndecan-3, annexin VI, and alkaline phosphatase) by human osteoarthritic chondrocytes," *American Journal of Pathology*, vol. 159, no. 5, pp. 1777–1783, 2001.
- [164] W. Wu, R. C. Billingham, I. Pidoux et al., "Sites of collagenase cleavage and denaturation of type II collagen in aging and osteoarthritic articular cartilage and their relationship to the distribution of matrix metalloproteinase 1 and matrix metalloproteinase 13," *Arthritis and Rheumatism*, vol. 46, no. 8, pp. 2087–2094, 2002.
- [165] J. Quintavalla, C. Kumar, S. Daouti, E. Slosberg, and S. Uziel-Fusi, "Chondrocyte cluster formation in agarose cultures as a functional assay to identify genes expressed in osteoarthritis," *Journal of Cellular Physiology*, vol. 204, no. 2, pp. 560–566, 2005.
- [166] A. Maroudas, M. T. Bayliss, and M. F. Venn, "Further studies on the composition of human femoral head cartilage," *Annals of the Rheumatic Diseases*, vol. 39, no. 5, pp. 514–523, 1980.

- [167] S. A. Semevolos, M. L. Strassheim, J. L. Haupt, and A. J. Nixon, "Expression patterns of hedgehog signaling peptides in naturally acquired equine osteochondrosis," *Journal of Orthopaedic Research*, vol. 23, no. 5, pp. 1152–1159, 2005.
- [168] T. Aigner, M. Hemmel, D. Neureiter et al., "Apoptotic cell death is not a widespread phenomenon in normal aging and osteoarthritic human articular knee cartilage: a study of proliferation, programmed cell death (apoptosis), and viability of chondrocytes in normal and osteoarthritic human knee cartilage," *Arthritis and Rheumatism*, vol. 44, no. 6, pp. 1304–1312, 2001.
- [169] K. Kühn, D. D. D'Lima, S. Hashimoto, and M. Lotz, "Cell death in cartilage," *Osteoarthritis and Cartilage*, vol. 12, no. 1, pp. 1–16, 2004.
- [170] H. Dumond, N. Presle, P. Pottier et al., "Site specific changes in gene expression and cartilage metabolism during early experimental osteoarthritis," *Osteoarthritis and Cartilage*, vol. 12, no. 4, pp. 284–295, 2004.
- [171] J. C. Fernandes, J. Martel-Pelletier, V. Lascau-Coman et al., "Collagenase-1 and collagenase-3 synthesis in normal and early experimental osteoarthritic canine cartilage: an immunohistochemical study," *Journal of Rheumatology*, vol. 25, no. 8, pp. 1585–1594, 1998.
- [172] E. V. Tchetina, M. Kobayashi, T. Yasuda, T. Meijers, I. Pidoux, and A. R. Poole, "Chondrocyte hypertrophy can be induced by a cryptic sequence of type II collagen and is accompanied by the induction of MMP-13 and collagenase activity: implications for development and arthritis," *Matrix Biology*, vol. 26, no. 4, pp. 247–258, 2007.
- [173] H. Lorenz, W. Wenz, M. Ivancic, E. Steck, and W. Richter, "Early and stable upregulation of collagen type II, collagen type I and YKL40 expression levels in cartilage during early experimental osteoarthritis occurs independent of joint location and histological grading," *Arthritis Research & Therapy*, vol. 7, no. 1, pp. R156–R165, 2005.
- [174] J. R. Matyas, P. F. Ehlers, D. Huang, and M. E. Adams, "The early molecular natural history of experimental osteoarthritis: I. Progressive discoordinate expression of aggrecan and type II procollagen messenger rna in the articular cartilage of adult animals," *Arthritis and Rheumatism*, vol. 42, no. 5, pp. 993–1002, 1999.
- [175] J. R. Matyas, D. Huang, M. Chung, and M. E. Adams, "Regional quantification of cartilage type II collagen and aggrecan messenger RNA in joints with early experimental osteoarthritis," *Arthritis and Rheumatism*, vol. 46, no. 6, pp. 1536–1543, 2002.
- [176] C. T. G. Appleton, D. D. McErlain, V. Pitelka et al., "Forced mobilization accelerates pathogenesis: characterization of a preclinical surgical model of osteoarthritis," *Arthritis Research & Therapy*, vol. 9, article R13, 2007.
- [177] F. Moldovan, J. Pelletier, F. C. Jolicoeur, J. M. Cloutier, and J. Martel-Pelletier, "Diacerhein and rhein reduce the ICE-induced IL-1 β and IL-18 activation in human osteoarthritic cartilage," *Osteoarthritis and Cartilage*, vol. 8, no. 3, pp. 186–196, 2000.
- [178] B. Rolaufts, J. M. Williams, M. Aurich, A. J. Grodzinsky, K. E. Kuettner, and A. A. Cole, "Proliferative remodeling of the spatial organization of human superficial chondrocytes distant from focal early osteoarthritis," *Arthritis and Rheumatism*, vol. 62, no. 2, pp. 489–498, 2010.
- [179] N. Miosge, M. Hartmann, C. Maelicke, and R. Herken, "Expression of collagen type I and type II in consecutive stages of human osteoarthritis," *Histochemistry and Cell Biology*, vol. 122, no. 3, pp. 229–236, 2004.
- [180] A. P. Hollander, I. Pidoux, A. Reiner, C. Rorabeck, R. Bourne, and A. R. Poole, "Damage to type II collagen in aging and osteoarthritis starts at the articular surface, originates around chondrocytes, and extends into the cartilage with progressive degeneration," *Journal of Clinical Investigation*, vol. 96, no. 6, pp. 2859–2869, 1995.
- [181] A. R. Poole, M. Alini, and A. P. Hollander, "Cellular biology of cartilage degradation," in *Mechanisms and Models in Rheumatoid Arthritis*, pp. 163–203, Academic Press, London, UK, 1995.
- [182] T. Aigner, A. Zien, A. Gehrsitz, P. M. Gebhard, and L. McKenna, "Anabolic and catabolic gene expression pattern analysis in normal versus osteoarthritic cartilage using complementary DNA-array technology," *Arthritis and Rheumatism*, vol. 44, no. 12, pp. 2777–2789, 2001.
- [183] M. Gebauer, J. Saas, J. Haag et al., "Repression of anti-proliferative factor Tob1 in osteoarthritic cartilage," *Arthritis Research & Therapy*, vol. 7, no. 2, pp. R274–R284, 2005.
- [184] A. C. Bay-Jensen, T. L. Andersen, N. Charni-Ben Tabassi et al., "Biochemical markers of type II collagen breakdown and synthesis are positioned at specific sites in human osteoarthritic knee cartilage," *Osteoarthritis and Cartilage*, vol. 16, no. 5, pp. 615–623, 2008.
- [185] D. Pfander, R. Rahmzadeh, and E. E. Scheller, "Presence and distribution of collagen II, collagen I, fibronectin, and tenascin in rabbit normal and osteoarthritic cartilage," *Journal of Rheumatology*, vol. 26, no. 2, pp. 386–394, 1999.
- [186] K. Veje, J. L. Hyllested-Winge, and K. Ostergaard, "Topographic and zonal distribution of tenascin in human articular cartilage from femoral heads: normal versus mild and severe osteoarthritis," *Osteoarthritis and Cartilage*, vol. 11, no. 3, pp. 217–227, 2003.
- [187] H. Lorenz and W. Richter, "Osteoarthritis: cellular and molecular changes in degenerating cartilage," *Progress in Histochemistry and Cytochemistry*, vol. 40, no. 3, pp. 135–163, 2006.
- [188] E. N. Blaney Davidson, E. L. Vitters, P. M. van der Kraan, and W. B. van den Berg, "Expression of transforming growth factor- β (TGF β) and the TGF β signalling molecule SMAD-2P in spontaneous and instability-induced osteoarthritis: role in cartilage degradation, chondrogenesis and osteophyte formation," *Annals of the Rheumatic Diseases*, vol. 65, no. 11, pp. 1414–1421, 2006.
- [189] N. Yatsugi, T. Tsukazaki, M. Osaki, T. Koji, S. Yamashita, and H. Shindo, "Apoptosis of articular chondrocytes in rheumatoid arthritis and osteoarthritis: correlation of apoptosis with degree of cartilage destruction and expression of apoptosis-related proteins of p53 and c-myc," *Journal of Orthopaedic Science*, vol. 5, no. 2, pp. 150–156, 2000.
- [190] P. Garnerio, X. Ayral, J. C. Rousseau et al., "Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis," *Arthritis and Rheumatism*, vol. 46, no. 10, pp. 2613–2624, 2002.
- [191] E. Gómez-Barrena, O. Sánchez-Pernaute, R. Largo, E. Calvo, P. Esbrit, and G. Herrero-Beaumont, "Sequential changes of parathyroid hormone related protein (PTHrP) in articular cartilage during progression of inflammatory and degenerative arthritis," *Annals of the Rheumatic Diseases*, vol. 63, no. 8, pp. 917–922, 2004.
- [192] M. Pombo-Suarez, M. T. Castaño-Oreja, M. Calaza, J. Gomez-Reino, and A. Gonzalez, "Differential upregulation of the three transforming growth factor beta isoforms in human

- osteoarthritic cartilage," *Annals of the Rheumatic Diseases*, vol. 68, no. 4, pp. 568–571, 2009.
- [193] C. J. Brew, P. D. Clegg, R. P. Boot-Handford, J. G. Andrew, and T. Hardingham, "Gene expression in human chondrocytes in late osteoarthritis is changed in both fibrillated and intact cartilage without evidence of generalised chondrocyte hypertrophy," *Annals of the Rheumatic Diseases*, vol. 69, no. 1, pp. 234–240, 2010.
- [194] T. Hayami, M. Pickarski, Y. Zhuo, G. A. Wesolowski, G. A. Rodan, and L. E. T. Duong, "Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis," *Bone*, vol. 38, no. 2, pp. 234–243, 2006.
- [195] T. Pufe, W. Petersen, B. Tillmann, and R. Mentlein, "The splice variants VEGF121 and VEGF189 of the angiogenic peptide vascular endothelial growth factor are expressed in osteoarthritic cartilage," *Arthritis and Rheumatism*, vol. 44, no. 5, pp. 1082–1088, 2001.
- [196] M. Sharif, J. Kirwan, N. Charni, L. J. Sandell, C. Whittles, and P. Garnero, "A 5-yr longitudinal study of type IIA collagen synthesis and total type II collagen degradation in patients with knee osteoarthritis—association with disease progression," *Rheumatology*, vol. 46, no. 6, pp. 938–943, 2007.
- [197] E. V. Tchetina, J. Antoniou, M. Tanzer, D. J. Zukor, and A. R. Poole, "Transforming growth factor- β 2 suppresses collagen cleavage in cultured human osteoarthritic cartilage, reduces expression of genes associated with chondrocyte hypertrophy and degradation, and increases prostaglandin E_2 production," *American Journal of Pathology*, vol. 168, no. 1, pp. 131–140, 2006.
- [198] W. Hui, T. Cawston, and A. D. Rowan, "Transforming growth factor β 1 and insulin-like growth factor 1 block collagen degradation induced by oncostatin M in combination with tumour necrosis factor α from bovine cartilage," *Annals of the Rheumatic Diseases*, vol. 62, no. 2, pp. 172–174, 2003.
- [199] J. Jiang, N. L. Leong, J. C. Mung, C. Hidaka, and H. H. Lu, "Interaction between zonal populations of articular chondrocytes suppresses chondrocyte mineralization and this process is mediated by PTHrP," *Osteoarthritis and Cartilage*, vol. 16, no. 1, pp. 70–82, 2008.
- [200] W. Kafienah, S. Mistry, S. C. Dickinson, T. J. Sims, I. Learmonth, and A. P. Hollander, "Three-dimensional cartilage tissue engineering using adult stem cells from osteoarthritis patients," *Arthritis and Rheumatism*, vol. 56, no. 1, pp. 177–187, 2007.
- [201] E. V. Tchetina, J. A. Di Battista, D. J. Zukor, J. Antoniou, and A. R. Poole, "Prostaglandin PGE_2 at very low concentrations suppresses collagen cleavage in cultured human osteoarthritic articular cartilage: this involves a decrease in expression of proinflammatory genes, collagenases and COL10A1, a gene linked to chondrocyte hypertrophy," *Arthritis Research & Therapy*, vol. 9, no. 4, p. R75, 2007.
- [202] J. Akaogi, T. Nozaki, M. Satoh, and H. Yamada, "Role of PGE_2 and EP receptors in the pathogenesis of rheumatoid arthritis and as a novel therapeutic strategy," *Endocrine, Metabolic & Immune Disorders-Drug Targets*, vol. 6, no. 4, pp. 383–394, 2006.
- [203] M. Attur, H. E. Al-Mussawir, J. Patel et al., "Prostaglandin E_2 exerts catabolic effects in osteoarthritis cartilage: evidence for signaling via the EP4 receptor," *Journal of Immunology*, vol. 181, no. 7, pp. 5082–5088, 2008.
- [204] D. D'Lima, J. Hermida, S. Hashimoto, C. Colwell, and M. Lotz, "Caspase inhibitors reduce severity of cartilage lesions in experimental osteoarthritis," *Arthritis and Rheumatism*, vol. 54, no. 6, pp. 1814–1821, 2006.
- [205] A. Scharstuhl, E. L. Vitters, P. M. van der Kraan, and W. B. van den Berg, "Reduction of osteophyte formation and synovial thickening by adenoviral overexpression of transforming growth factor β /bone morphogenetic protein inhibitors during experimental osteoarthritis," *Arthritis and Rheumatism*, vol. 48, no. 12, pp. 3442–3451, 2003.
- [206] A. C. Lin, B. L. Seeto, J. M. Bartoszko et al., "Modulating hedgehog signaling can attenuate the severity of osteoarthritis," *Nature Medicine*, vol. 15, no. 12, pp. 1421–1425, 2009.
- [207] E. Araldi and E. Schipani, "MicroRNA-140 and the silencing of osteoarthritis," *Genes and Development*, vol. 24, no. 11, pp. 1075–1080, 2010.
- [208] S. S. Glasson, R. Askew, B. Sheppard et al., "Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis," *Nature*, vol. 434, no. 7033, pp. 644–648, 2005.
- [209] S. Kamekura, Y. Kawasaki, K. Hoshi et al., "Contribution of runt-related transcription factor 2 to the pathogenesis of osteoarthritis in mice after induction of knee joint instability," *Arthritis and Rheumatism*, vol. 54, no. 8, pp. 2462–2470, 2006.
- [210] A. R. Klatt, G. Klinger, O. Neumüller et al., "TAK1 downregulation reduces IL-1 β induced expression of MMP13, MMP1 and TNF-alpha," *Biomedicine and Pharmacotherapy*, vol. 60, no. 2, pp. 55–61, 2006.
- [211] J. Weisser, B. Rahfoth, A. Timmermann, T. Aigner, R. Bräuer, and K. von der Mark, "Role of growth factors in rabbit articular cartilage repair by chondrocytes in agarose," *Osteoarthritis and Cartilage*, vol. 9, pp. S48–S54, 2001.
- [212] T. Yamamoto, S. Wakitani, K. Imoto et al., "Fibroblast growth factor-2 promotes the repair of partial thickness defects of articular cartilage in immature rabbits but not in mature rabbits," *Osteoarthritis and Cartilage*, vol. 12, no. 8, pp. 636–641, 2004.
- [213] P. R. Elford, M. Graeber, H. Ohtsu et al., "Induction of swelling, synovial hyperplasia and cartilage proteoglycan loss upon intra-articular injection of transforming growth factor β -2 in the rabbit," *Cytokine*, vol. 4, no. 3, pp. 232–238, 1992.
- [214] S. B. Trippel, "Growth factor inhibition: potential role in the etiopathogenesis of osteoarthritis," *Clinical Orthopaedics and Related Research*, no. 427, pp. S47–S52, 2004.
- [215] J. I. Shida, S. Jingushi, T. Izumi, T. Ikenoue, and Y. Iwamoto, "Basic fibroblast growth factor regulates expression of growth factors in rat epiphyseal chondrocytes," *Journal of Orthopaedic Research*, vol. 19, no. 2, pp. 259–264, 2001.
- [216] P. C. Yeager, T. L. Masi, J. L. Buck de Ortiz, F. Binette, R. Tubo, and J. M. McPherson, "Synergistic action of transforming growth factor- β and insulin-like growth factor-I induces expression of type II collagen and aggrecan genes in adult human articular chondrocytes," *Experimental Cell Research*, vol. 237, no. 2, pp. 318–325, 1997.
- [217] A. Barbero, S. Grogan, D. Schäfer, M. Heberer, P. Mainil-Varlet, and I. Martin, "Age related changes in human articular chondrocyte yield, proliferation and post-expansion chondrogenic capacity," *Osteoarthritis and Cartilage*, vol. 12, no. 6, pp. 476–484, 2004.
- [218] A. V. Babarina, U. Möllers, K. Bittner, P. Vischer, and P. Bruckner, "Role of the subchondral vascular system in endochondral ossification: endothelial cell-derived proteinases derepress late cartilage differentiation in vitro," *Matrix Biology*, vol. 20, no. 3, pp. 205–213, 2001.

- [219] J. O. P. Cheung, M. C. Hillarby, S. Ayad et al., "A novel cell culture model of chondrocyte differentiation during mammalian endochondral ossification," *Journal of Bone and Mineral Research*, vol. 16, no. 2, pp. 309–318, 2001.
- [220] M. J. Zuscik, J. F. Baden, Q. Wu et al., "5-azacytidine alters TGF- β and BMP signaling and induces maturation in articular chondrocytes," *Journal of Cellular Biochemistry*, vol. 92, no. 2, pp. 316–331, 2004.
- [221] M. L. Ho, J. E. K. Chang, S. C. Wu et al., "A novel terminal differentiation model of human articular chondrocytes in three-dimensional cultures mimicking chondrocytic changes in osteoarthritis," *Cell Biology International*, vol. 30, no. 3, pp. 288–294, 2006.
- [222] T. Yasuda, E. Tchetina, K. Ohsawa et al., "Peptides of type II collagen can induce the cleavage of type II collagen and aggrecan in articular cartilage," *Matrix Biology*, vol. 25, no. 7, pp. 419–429, 2006.
- [223] T. Yasuda and A. R. Poole, "A fibronectin fragment induces type II collagen degradation by collagenase through an interleukin-1-mediated pathway," *Arthritis and Rheumatism*, vol. 46, no. 1, pp. 138–148, 2002.
- [224] G. A. Homandberg, "Cartilage damage by matrix degradation products: fibronectin fragments," *Clinical Orthopaedics and Related Research*, no. 391, pp. S100–S107, 2001.
- [225] R. Serra, M. Johnson, E. H. Filvaroff et al., "Expression of a truncated, kinase-defective TGF- β type II receptor in mouse skeletal tissue promotes terminal chondrocyte differentiation and osteoarthritis," *Journal of Cell Biology*, vol. 139, no. 2, pp. 541–552, 1997.
- [226] T. F. Li, M. Darowish, M. J. Zuscik et al., "Smad3-deficient chondrocytes have enhanced BMP signaling and accelerated differentiation," *Journal of Bone and Mineral Research*, vol. 21, no. 1, pp. 4–16, 2006.
- [227] G. Valverde-Franco, J. S. Binette, . et al., "Defects in articular cartilage metabolism and early arthritis in fibroblast growth factor receptor 3 deficient mice," *Human Molecular Genetics*, vol. 15, no. 11, pp. 1783–1792, 2006.
- [228] C. T. G. Appleton, S. E. Usmani, S. M. Bernier, T. Aigner, and F. Beier, "Transforming growth factor α suppression of articular chondrocyte phenotype and Sox9 expression in a rat model of osteoarthritis," *Arthritis and Rheumatism*, vol. 56, no. 11, pp. 3693–3705, 2007.
- [229] M. B. Goldring and K. B. Marcu, "Cartilage homeostasis in health and rheumatic diseases," *Arthritis Research & Therapy*, vol. 11, no. 3, article 224, 2009.
- [230] D. L. Cecil, K. Johnson, J. Rediske, M. Lotz, A. M. Schmidt, and R. Terkeltaub, "Inflammation-induced chondrocyte hypertrophy is driven by receptor for advanced glycation end products," *Journal of Immunology*, vol. 175, no. 12, pp. 8296–8302, 2005.
- [231] D. Merz, R. Liu, K. Johnson, and R. Terkeltaub, "IL-8/CXCL8 and growth-related oncogene α /CXCL1 induce chondrocyte hypertrophic differentiation," *Journal of Immunology*, vol. 171, no. 8, pp. 4406–4415, 2003.
- [232] C. Baugé, F. Legendre, S. Leclercq et al., "Interleukin-1 β impairment of transforming growth factor β 1 signaling by down-regulation of transforming growth factor β receptor type II and up-regulation of Smad7 in human articular chondrocytes," *Arthritis and Rheumatism*, vol. 56, no. 9, pp. 3020–3032, 2007.